Astellas has announced that its subsidiary, Xyphos Biosciences, has entered into a research collaboration and license ...
Santhera Pharmaceuticals has announced the publication of results in the journal Neurology that support the long-term ...
Johnson & Johnson (J&J) has announced that a reduced dosing frequency of Tecvayli (teclistamab-cqyv) has been approved by the US Food and Drug Administration (FDA) for certain patients with relapsed ...
Pathways to Antimicrobial Clinical Efficacy (PACE) has announced its first partnership with the UK Health Security Agency (UKHSA) to support the development of new antimicrobials to tackle ...
Almirall has entered into an exclusive licence agreement with Novo Nordisk to gain rights to develop its IL-21-blocking monoclonal antibody for immune inflammatory dermatological diseases. Novo’s ...
Pfizer’s S1P receptor modulator Velsipity (etrasimod) has been approved by the European Commission (EC) to treat moderately-to-severely active ulcerative colitis (UC) in patients aged 16 years and ...
Novartis has announced that the Scottish Medicines Consortium has approved Consentyx (secukinumab) to treat adults with active moderate-to-severe hidradenitis suppurativa (HS) in Scotland on the NHS.
AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) in combination with chemotherapy to treat a subset of advanced lung cancer patients. The ...
UCB's bimekizumab has demonstrated sustained efficacy and symptom improvement in patients with hidradenitis suppurativa (HS), according to late-stage results presented at this year’s Conference of the ...
GSK’s Omjjara (momelotinib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment option for myelofibrosis-related splenomegaly or symptoms in adults with ...
Pfizer’s Litfulo (ritlecitinib) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat severe alopecia areata in patients aged 12 years and older. NICE’s ...